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ABSTRACT: Prostate cancer (PCa) therapy typically involves administration of “classical” antiandrogens, competitive inhibitors
of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in
the ligand-binding domain (LBD) of AR. Prolonged LBP-targeting leads to resistance, and alternative therapies are urgently
required. We report the identification and characterization of a novel series of diarylhydrazides as selective disruptors of AR
interaction with coactivators through application of structure and ligand-based virtual screening. Compounds demonstrate full
(“true”) antagonism in AR with low micromolar potency, selectivity over estrogen receptors α and β and glucocorticoid receptor,
and partial antagonism of the progesterone receptor. MDG506 (5) demonstrates low cellular toxicity in PCa models and dose
responsive reduction of classical antiandrogen-induced prostate specific antigen expression. These data provide compelling
evidence for such non-LBP intervention as an alternative approach or in combination with classical PCa therapy.
■ INTRODUCTION
Prostate cancer (PCa) is one of the major causes of cancer
death in men worldwide.1 The molecular basis of the disease
involves an irregular behavior of the functions mediated by the
androgen receptor (AR). Human AR belongs to the nuclear
receptor (NR) superfamily of transcription factors, which
regulate gene transcription upon ligand binding.2 The structure
of NRs is extensively documented in the literature,3 and in
general, NRs share the following common organization: a
variable amino-terminal activation function domain (AF-1), a
highly conserved DNA-binding domain (DBD), a hinge region
that contains the nuclear localization signal, a conserved C-
terminal ligand-binding domain (LBD) comprising a 12 helical
structure that encloses a central ligand binding pocket (LBP),
and a second activation function domain (AF-2) that is located
at the carboxy-terminal end of the LBD and mediates ligand-
dependent transactivation.
AR is activated by the endogenous hormone testosterone
(tes) and its more potent metabolite dihydrotestosterone
(DHT), both of which bind in the LBP. The binding of these
endogenous modulators induces a reorganization of helix 12 to
the so-called “agonist” conformation, generating a structured
hydrophobic surface (AF-2) suitable for the recruitment of
tissue-specific NR coactivators. Such NR coactivators can be
thought of as “master switches”, directing and amplifying the
subsequent transcriptional activity of the target NR. In a recent
work, an additional secondary function site called binding
function 3 (BF-3) has been reported on the surface of the AR
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that could also play a relevant role in the allosteric modulation
of the AF-2.4
NR drug development has traditionally focused on advancing
full or partial agonists/antagonists interacting within the LBP of
the LBD.5 PCa has been treated by intervention at the early
stages through utility of classical antiandrogens, which act by
displacing the natural hormones from the pocket and inducing
a conformational change of the helix 12 so that coactivators
cannot be recruited. Tissue specificity, detrimental side effects,
and a loss of the pharmacological effect (acquired drug
resistance) over time are major and ongoing concerns with
such LBP targeting treatment regimes.6,7
It has been demonstrated that it is possible to inhibit the
transcriptional activity of the NRs by directly blocking the
critical receptor:coactivator interaction.8−13 This alternative
approach to traditional NR modulation may furnish greater
pharmacological insight and afford opportunities to modulate
not only under tissue specific circumstances but without
adversely affecting natural ligand binding and so preserving the
beneficial/nondisease linked functions of the receptors.
Specifically, the steroid receptor coactivator (SRC) family has
been postulated as a feasible target for pharmacological
intervention.14 The viability of targeting AR−coactivator
interaction using small molecules has been recently demon-
strated.4,8 Moreover, it has been postulated that circumventing
the LBP will overcome the problem of drug resistance in
PCa.15−19
Here we describe the discovery and characterization of a
novel class of selective non-LBP “true” antiandrogens,
characterized by full AR antagonism in inhibiting the
recruitment of coactivators and lacking intrinsic partial agonistic
properties. Mechanistically, these compounds are totally
differentiated from the recent description of true LBP
antiandrogens like MDV3100 and RD162,20,21 while their
selectivity and druglike nature underpin the potential of a non-
LBP intervention strategy in advanced prostate cancer resistant
Figure 1. Virtual screening and identification of diarylhydrazide scaffolds. (A) A series of coactivator peptides cocrystallized in the AF-2 groove was
employed; for illustrative purposes we present the FxxLF coactivator motif from PDB entry 1T7R. The AF-2 groove is represented in dark gray. For
clarity reasons, only Lys720 and Glu897 are shown and DHT is not illustrated;23 (B) A 3D pharmacophore model was derived containing the
common features between AR coactivators and the two aromatic features of the FxxLF motif. Pharmacophores were used to screen vendor
compound databases and to guide the docking of putative “hits” into the AF-2 site. The screen identified an active diarylhydrazide class of
compounds. (C, D) Two first round actives 1 (MDG173) and 2 (MDG15) docked poses in the AF-2 site, with the surface rendered and only key
amino acids shown. Partial mapping of initial hits to the pharmacophore suggested additional virtual screening to identify more potent family
members. Images were generated with Molecular Operating Environment (MOE)25 and PyMol.26
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to “classical therapy”, first described for the true non-LBP
targeting antiandrogens pyrvinium pamoate (PP) and harmol
hydrochloride (HH).22
The biological data obtained both on target with time-
resolved fluorescence resonance energy transfer (TR-FRET)/
fluorescence polarization (FP) assays and in cellular PCa
models demonstrate the non-LBP antagonist activity of the
series and an alternative mechanism of inhibition, furnishing a
new class of nonpeptidic, small molecule AR:coactivator
selective disruptors as leads for the development of novel
treatments for prostate cancer.
■ RESULTS
Virtual Screening. A virtual (computational) screen of six
vendor compound databases (see Experimental Section) was
performed through a combination of 3D pharmacophore
generation and docking. Seven X-ray structures of coactivator
peptide bound AR were used to define key ligand-derived
pharmacophoric features of the most represented motifs
occurring in known AR coactivators.23 Initially, common key
interaction motifs within the peptide of the form FxxLF, LxxLL,
or FxxLW were considered to generate a consensus AF-2
pharmacophore. Subsequently, a second site-derived pharma-
cophore model was advanced based on the specific character-
istics of the androgen receptor AF-2 region, which demon-
strates known selectivity toward the FxxLF coactivator motif24
(Figure 1B). The cocrystallization of the AR LBD bound with
DHT in the presence of the FxxLF peptide (PDB ID 1T7R)23
provided the structural basis of the AF-2 interaction for docking
studies.
From the virtual screen, a first series of compounds with
predicted target affinity was selected from commercially
available databases (see Experimental Section) and evaluated
for biological activity using TR-FRET and FP techniques. This
initial screen (Figures 1C,D and 2) identified two small
molecules, 1 and 2, both diarylhydrazides, as possible non-LBP
AR antagonists. Non-LBP modulatory activity was evidenced
by demonstration of an IC50 in the range of 50−100 μM in AR
TR-FRET coactivator displacement assay and their inability to
displace bound fluorescently labeled ligand from the LBP
through an FP assay. These first round “hit” molecules map
only partially to the screening pharmacophore (Figure 1C,D).
Accordingly, an optimization round of screening was initiated
to explore the utility of the scaffold for more effective
disruption of AR:coactivator interaction.
From these initial data, a simple molecular similarity search
was performed (Tanimoto coefficient >70%) to furnish a new
screening series of 37 compounds bearing the desired
diarylhydrazide scaffold. This second round screen identified
four small molecules (Figure 2), 3 (MDG 483), 4 (MDG 292),
5 (MDG 506), and 6 (MDG 508), with improved activity (IC50
< 50 μM in an AR TR-FRET assay). These ligands were taken
forward for additional investigation and characterization.
Diarylhydrazides Inhibit FxxLF Coactivator Recruit-
ment by AR without Traditional Antagonism of the LBP.
The series of diaryl-substituted hydrazides identified through
the VS process (Figure 2) inhibited the recruitment of the
fluorescent labeled D11-FxxLF coactivator peptide in the
presence of an agonist (DHT) concentration equal to EC80
using time-resolved FRET assays. D11-FxxLF is a peptide
developed from random phage display technology that
resembles the SRC family of coactivator proteins in its flanking
sequence but that also has an AR N-terminal interaction
domain.24 Thus, it is a biological mimic of the N-terminal and
the SRC coactivator interactions with the LBD.
A 12-point dose−response curve was determined for those
compounds that inhibited coactivator binding in the micro-
molar range, acting as full AR antagonists, 3−6 (Figure 3A and
Table 1).
Maximal activity was calculated as per established methods.27
The background signal, representing diffusion-enhanced FRET
in the absence of AR, was subtracted from the FRET value of
Figure 2. Diaryl-substituted hydrazides retrieved from the virtual screening process.
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each compound and from the maximal signal, representing
FxxLF-bound AR in presence of DHT.
−
− ×
(FRET signal background)
/(FRET max signal background) 100
compound
DMSO
The TR-FRET assay cannot differentiate between direct
coactivator antagonists acting on the LBD surface and classical
AR antagonists, which also functionally disrupt coactivator
recruitment by displacing DHT from the ligand binding pocket.
To characterize the nature of the antagonist effect, compounds
were tested for their ability to displace a potent fluorescent
ligand (fluorophore) from the AR LBP through a fluorescence
polarization (FP) assay at a single point concentration (50
μM), using cyproterone acetate (CPA) at the same
concentration as a reference, a known AR LBP-mediated
antagonist. All compounds tested showed 0% inhibition of the
AR-LBD and fluorophore complex, indicating a non-LBP-
mediated mechanism of AR transactivation inhibition (Figure
3C).
Compound 3 gave an unusually high value of millipolariza-
tion units (mP), 20% higher than the maximal control (Figure
3C). This could be indicative of solubility issues in the assay
buffer and therefore could generate a false negative result. It is
known that FP assay outcomes can be influenced by intrinsic
fluorescence of the test compounds and/or light scattering
phenomena due to poor solubility and precipitation. To
minimize the possibility of such false negative or positive
reporting, the FP data was rigorously interrogated through
examination of both autofluorescence and aggregation. None of
the compounds tested showed competing autofluorescence in
the assay conditions or was shown to be a false negative.
Results are shown in the Supporting Information (Supple-
mentary Figure 2).
Figure 3. Diarylhydrazides inhibit the AR recruitment of a fluorescent-labeled D11-FxxLF peptide but do not displace a potent fluorescent ligand
from the AR-LBP. (A and B) Compounds were tested in a TR-FRET assay across a concentration range from 100 μM to 45 nM in the presence of a
concentration of DHT = EC80 in AR-LBD wt (A) and AR-LBD T877A (B). Data points represent the mean of two independent experiments
performed in triplicate. Error bars represent the standard error of the mean (SEM) for n = 6 values. Data was fitted using log antagonist
concentration vs response (variable slope) with GraphPad Prism 5 (see Experimental Section for details). (C) Fluorescence polarization data is
plotted as percent maximal activity represented by AR-LBD and fluorophore complex (0% inhibition). The minimum control value represents free
fluorophore (Free F) in solution (100% inhibition). Error bars represent the SEM for n = 6 values.
Table 1. Diarylhydrazides Activity toward AR and
ART877Aa
compounds AR (wt) AR T877A
3 15.9 ± 3.2 μM 11.1 ± 3.2 μM
4 13.3 ± 3.1 μM 12.4 ± 2.2 μM
5 26.3 ± 3.8 μM 33.2 ± 5.9 μM
6 17.9 ± 6.9 μM 28.1 ± 6.7 μM
aIC50 values are shown as ±SEM (n = 6). Activity data are in
agreement for 4 and 5 in both AR wt and ART877A. The higher
confidence mP values and experimental reproducibility obtained for 4
and 5 in coactivator studies were used as the basis to advance these
compounds to cellular characterization and receptor subtype selectivity
evaluations.
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To further validate the utility of these ligands in PCa, on-
target binding experiments were also performed using the
recombinant T877A AR mutant28,29 characteristic of advanced
stage androgen-independent PCa. In TR-FRET, the com-
pounds demonstrated similar activity to that observed in the
wild type assays, indicating their potential in advanced phases of
prostate cancer (Figure 3B).
Diarylhydrazides Are AR Selective Coactivator Inter-
action Disruptors. We undertook to profile the selectivity of
these compounds for AR over other members of the same
phylogenetic branch of the steroidal nuclear receptor subfamily.
Compound binding affinities for progesterone receptor (PR),
glucocorticoid receptor (GR), estrogen receptor α (ER-α), and
estrogen receptor β (ER-β) were determined using TR-FRET
(Table 2). Diarylhydrazides do not displace fluorescent-labeled
coactivator PGC-1α from estradiol−ER-α and estradiol−ER-β
complex and do not displace fluorescent-labeled coactivator
SRC1-4 from dexamethasone−GR complex at concentrations
up to 100 μM (Supporting Information, Supplementary Figures
3−5). Compound 5 binds PR with comparable affinity to that
observed for AR, while 4 demonstrates approximately 2-fold
binding selectivity for the AR over PR.
In functional evaluation we determined that the diary-
lhydrazide compounds are full AR antagonists, with a partial
antagonistic profile demonstrated in PR, displacing SRC1−4
from progesterone−PR complex at micromolar concentrations
(Figure 4 and Table 2).
The non-LBP nature of this interaction was confirmed by an
FP assay (Supporting Information, Supplementary Figure 6).
Diarylhydrazides Demonstrate Low Toxicity in Differ-
ent Prostate Cancer Cellular Models. To ascertain the
translational (clinical) potential of these ligands, compounds
were evaluated in cellular models of prostate cancer (LNCaP,30
an androgen-dependent cell line and PC-3,31 an androgen-
independent cell line) and in normal prostatic epithelia cell line
PWR-1E.32 Cell viability was assessed after 24 h of incubation
with the test compounds at three different concentrations
(Figure 5). The classical antiandrogen CPA was used as a
reference, showing a minor effect at 50 μM in the androgen
independent cell line PC-3. At 50 μM 4 reduces cell viability to
a 50−60%, whereas 5 acts consistently across the three cell
lines, retaining cell viability at around 80%. These data
suggested 5 as a potential candidate for further functional
characterization.
Compound 5 Reduces DHT-Dependent Cell Prolifer-
ation in LNCaP. The diarylhydrazides were evaluated for their
effects on the AR signaling pathway and on hormone-
dependent cellular growth of LNCaP cells. Compound 5 was
well-tolerated after 5 days of treatment at 10 and 20 μM
concentrations and enabled observation of a specific reduction
in DHT-treated cell count (Figure 6A).
Compound 5 Reduces DHT- and CPA-Stimulated PSA
Expression in LNCaP Cells. Prostate specific antigen (PSA) is
a serine protease normally secreted by the prostate epithelia. Its
expression is under the control of AR. PSA is widely used as a
marker for PCa33, as its serum levels are increased in this
condition. Compound 5 was shown to reduce DHT-induced
PSA secretion in a dose−response fashion as quantified by an
ELISA experiment in LNCaP cells (Figure 6B).
It is well-documented that classical antiandrogens (i.e., those
binding within the LBP/competing with endogenous ligands)
have partial agonistic properties, which make them less useful in
the management of advanced prostate cancer.34 Arising from
this inherent agonism, in an androgen-deprived LNCaP cell
line, antiandrogens such as CPA can actually activate the AR
pathway and stimulate cell growth.35 In direct contrast to the
behavior of traditional antagonists, 5 shows no detectable
agonist or partial agonist activity at tested concentrations,
consistent with an alternative mechanism to that of the classical
antiandrogens. Finally, treatment with 5 at 10 μM was found to
antagonize CPA partial agonist activity (measured as secreted
PSA levels in the cellular media in an ELISA experiment),
suggesting its potential benefit in combination therapy for
advanced stages of prostate cancer (Figure 6C). To further
challenge this hypothesis, the compounds were characterized in
the 22Rv1 cell line.36 This castration resistant cell line expresses
the AR H874Y mutation. The compounds also demonstrated
Table 2. Diarylhydrazides Activity (IC50, μM) in GR, ER-α/
ER-β, and PR Nuclear Receptor Targetsa
compounds GR ER-α ER-β PR
4 NA (>100) NA (>100) NA (>100) 22.5 ± 5.4
5 NA (>100) NA (>100) NA (>100) 27.7 ± 7.3
aData are presented as averages of at least two independent
experiments. IC50 values are shown as ±SEM (n = 6). NA = not
active at 100 μM.
Figure 4. Compounds 4 and 5 are partial antagonists for PR. Compounds were tested at a concentration range from 100 to 1 μM in the presence of
a concentration of progesterone = EC80. Data points represent the mean of two independent experiments in triplicate. Error bars represent the
standard error of the mean (SEM) for n = 6 values. Data was fitted using log antagonist concentration vs response (variable slope) with GraphPad
Prism 5 (see Experimental Section for details). Compounds 4 and 5 show 50% and 30% inhibition respectively at 100 μM. IC50 values are shown in
Table 2.
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similar effects in this alternate system, supporting the
hypothesis of their functioning as true antiandrogens
(Supporting Information, Supplementary Figure 7).
■ DISCUSSION
Classical antiandrogen therapy is known to have limited
beneficial effects in hormone-insensitive PCa. Alternative AR
inhibitors are therefore needed in the treatment of PCa. In this
study, we demonstrate the successful implementation of a
virtual screening approach in the identification of small
molecule AR modulators, where the structural motif of AR
coactivators was included in a 3D pharmacophore. We report
the discovery, identification, and characterization of a novel
series of diarylhydrazide non-LBP-binding antiandrogen
compounds, with demonstrated ability to displace AR
coactivators and with established potency in AR-dependent
prostate cancer cell lines. Activity was measured with a TR-
FRET assay and a non-LBP-mediated mechanism of inhibition
was confirmed by FP assay. These compounds are shown to
function without any demonstrated intrinsic or partial agonist
activity in AR and therefore can be classified as true5 non-LBP
antiandrogens.
The nature of NR coactivators and the high homology of NR
coactivator binding sites are such that, to more fully profile the
potential utility of these ligands, their selectivity was evaluated
across members of the subclass of steroid receptors, including
ER-α and ER-β, GR, AR, and PR.
The selectivity of the diarylhydrazide scaffold for the AR was
demonstrated through TR-FRET evaluation in the estrogen
and glucocorticoid receptors, where agonist bound receptor
recruitment of coactivator was unimpaired at screening
concentrations up to 100 μM.
We additionally investigated the potential cytotoxicity of the
diarylhydrazides in three different cell lines, selecting 5 for its
Figure 5. Cell viability profile in LNCaP, PC-3, and PWR-1E cell lines. %Percent cell viability is plotted against the molar compound concentrations.
Compounds were tested at 5 × 10−5, 1 × 10−5, and 5 × 10−7 M. Error bars represent the SEM of two independent experiments done in triplicate (n
= 6).
Figure 6. Effect of compound 5 on DHT- and CPA-stimulated cell proliferation. (A and B) 5 reduces androgen-stimulated cell growth and DHT-
dependent AR signaling measured as PSA levels secreted in the cellular media in a dose-dependent fashion. (C) 5 at 10 μM reduces CPA-induced
AR signaling (in absence of androgens) measured as PSA levels secreted in the cellular media in a dose-dependent fashion. Data are presented as the
mean of two independent experiments, and bars show SEM for n = 6 values (A). Secreted PSA (ng/mL) was measured considering the optical
density at 450 nm minus the optical density at 540 nm and interpolating the values from the standard curve. Data are presented as mean of two
independent experiments, and bars show SEM for n = 4 values (B and C).
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favorable cytotoxic profile (cell viability was retained at around
80% in different prostatic cellular models).
Unmodified diarylhydrazide screening hits were also shown
to have 2-fold selectivity for AR over PR, with partial antagonist
activity demonstrated for the scaffolds in a PR functional assay,
remarkable given the high (>60%) homology of these NR
family members.2,37 Futhermore, given the established utility of
mifepristone (a PR modulator which also has antiandrogenic
activity) in the treatment of castration resistant prostate
cancer,38,39 the narrower selectivity window observed for
these AR ligands in PR over the other NR’s assessed is not a
significant concern in the context of the therapeutic area under
consideration.
Classical antiandrogens can be also distinguished for their
different behaviors at a cellular level. Save for two recent
examples,20,21 all LBP antiandrogens described to date have
also intrinsic partial agonist activity,34 demonstrated by
induction of PSA in the absence of hormone stimulation in
LNCaP cells. In this study, the novel non-LBP diarylhydrazide
antiandrogen 5 did not induce PSA expression in absence of
hormone stimulation when compared to CPA. In androgen-
deprived LNCaP cells, 5 reduces PSA expression in
combination with CPA, antagonizing its partial agonist activity
in a dose responsive fashion. This result supports the
hypothesis of a nonclassical mechanism of AR inhibition for
these diarylhydrazide ligands and it also demonstrates the
potential application of these and other non-LBP antiandrogen
small molecules targeting alternative AR sites in combination
with existing prostate cancer therapy.
■ CONCLUSION
Through application of virtual screening methodologies, we
present and characterize novel diarylhydrazide scaffolds as true
antiandrogensdisplacing AR−coactivator interaction and
having a full antagonistic profile on AR (both wt and
T877A), partial antagonistic profile for PR, and selectivity for
the other members of the NR-3 family (GR, ER-α, and ER-β).
The initial small molecule non-LBP true AR modulators
provided by this study will be used to further characterize the
AR−coactivator interface, to understand the basis of selectivity,
and to further guide rational drug design in the search of other
novel scaffolds directed at this interface. Chemical optimization
of the hydrazide linker to afford more tractable “druglike”
compounds is currently underway.
■ EXPERIMENTAL SECTION
Time-Resolved Fluorescence Resonance Energy Transfer
(TR-FRET). Lanthascreen TR-FRET AR Coactivator Assay Kit
(Invitrogen, cat no. PV4381) was used to screen for potential
coactivator disruptors. Black, low volume, 384-well assay plates
(Corning, NY, cat. no. 3676) were used to perform the assay (total
volume 20 μL), and TR-FRET signal was measured with PHERAstar
equipment (BMG LabTech) using a Lanthascreen optic module
(excitation, 335 nm; emission, 520 nm channel A and 495 nm channel
B).
TR-FRET values were calculated at 10 flashes per well, using a delay
time of 100 μs and integration time 200 μs as recommended by the
Invitrogen assay guidelines. The ratio 520 nm/495 nm was then
calculated and plotted against the concentration. A serial dilution of
compounds was first prepared in 100× DMSO (Sigma-Aldrich)
starting from the maximum desired concentration to achieve a 12
point range concentration using 96-well polypropylene plates
(Nalgene Nunc, Rochester, NY). Each 100× solution was diluted to
2× concentration with TR-FRET coregulator buffer A (Invitrogen
proprietary buffer), yielding a final concentration of 1% DMSO in each
well. Ten microliters of 2× solution was then added to the 384-well
plate, following addition of 5 μL of 4× AR-LBD and 5 μL of D11-
FxxLF/Tb anti-GST antibody in agonist mode and 5 μL of D11-
FxxLF/Tb anti-GST antibody/DHT (included at a concentration
equal to EC80 as determined by running the assay in agonist mode
first).
= + −EC 1080 {(log EC ) [(1/Hill slope) log[80/(100 80)]]}50
D11-FxxLF and Tb antibody were premixed in light protecting vials
prior to use. A final concentration of 5 mM DTT was used in the assay
buffer in order to prevent protein degradation. All plates (agonist and
antagonist mode) were incubated between 2 and 4 h at room
temperature protected from light prior to TR-FRET measurement.
IC50 values were determined by testing each ligand at concentrations
ranging from 100 μM to 45 nM using 2- and 3-fold dilutions to
generate a 12 point dose−response curve. Data was fitted using the
sigmoidal dose response (variable slope) available from Graphpad
Prism 5.40
= + −
+ −( )
Y Bottom (Top Bottom)
1 10 X[(log IC )(Hill slope)]50
The Z factor for these assays was >0.5, as calculated by the equation
provided by Zhang et al.41
= −
σ + σ
|μ − μ |
Z
x
1
3 ( )p n
p n
In line with the assay protocol, a known agonist, dihydrotestoster-
one (DHT, cat no. A8380, Sigma), and a known antagonist,
cyproterone acetate (cat no. C3412, Sigma), were used as controls
in the assay. A control with no AR-LBD present was included to
account for diffusion-enhanced FRET or ligand-independent coac-
tivator recruitment. A negative control with 2× DMSO was present to
account for any solvent vehicle effects.
The same procedure was used for AR T877A (Invitrogen cat no.
PV4667), PR (Invitrogen cat no. PV4666), ER-α (Invitrogen cat no.
PV4544), ER-β (Invitrogen cat no. PV4541), and GR (Invitrogen cat
no. PV4683). The assay was adapted to exclude possible nonspecific
aggregation mechanism of inhibition by adding very low concentration
of detergent Triton X-100 (0.01%) to the assay buffer following the
Shoichet review guidelines42 (Supporting Information, Supplementary
Figure 1).
Fluorescence Polarization (FP). PolarScreen Androgen Receptor
Competitor Assay Kit Green (Invitrogen, cat no. P3018) was used to
investigate the binding of the test compound to the LBP site, occupied
by a high-affinity fluorophore ligand (Fluormone).
The 100× test compound solutions in DMSO were diluted in AR
green buffer (Invitrogen) to achieve 2× concentrations and placed in a
384-well plate (Corning, cat no. 3576) with 40 μL volume capacity.
AR-LBD was supplemented with 5 mM DTT to prevent protein
degradation. AR-LBD and Fluormone (2×) mix were prepared
separately and then added to each compound dilution to achieve a
final concentration LBD-Fluormone of 50 and 2 nM, respectively.
Plates were incubated protected from light for at least 4 h. Controls
included a maximum mP positive control, which consists of the AR-
LBD and Fluormone mix (2×), and a minimum mP control,
containing only Fluormone (2×). A vehicle control was added to
account for DMSO effect, and a blank control containing buffer only.
Fluorescence polarization was measured with PHERAstar equipment
(BMG LabTech) using an optic module with excitation at 485 nm and
emission at 530 nm.
Cell Culture. LNCaP cells (androgen-dependent), PC-3 (andro-
gen-independent), and PWR-1E (normal prostatic epithelia) were
cultured in RPMI-1640 GlutaMAX (Invitrogen), F12K (Invitrogen),
and K-SFM media (Invitrogen). The first two were supplemented with
10% fetal bovine serum (FBS), penicillin (100 units/mL), and
streptomycin (100 μg/mL). K-SFM was supplemented with 5 ng/mL
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epidermal growth factor (EGF) and 0.05 mg/mL bovine pituitary
extract (BPE). Cells were propagated at 1:3 or 1:6 dilutions at 37 °C
in 5% CO2.
Cell Viability and Cell Proliferation Assays. For cell viability
(end point) assays LNCaP, PC-3, and PWR-1E cells were seeded at
2.5 × 104/mL density in 200 μL volume of a 96-well plate in triplicate
and incubated for 24 h prior testing. Test compounds were included at
different concentrations to achieve a final concentration of 0.5%
DMSO in each well. The effect of 0.5% DMSO on cell viability was
also evaluated. Cell viability was assessed after 24 h of treatment using
10% AlamarBlue reagent (Invitrogen) for each well. Cell viability was
monitored by the reduction of resazurin, a blue, cell-permeable,
nontoxic compound, to resorufin, a red and highly fluorescent product.
Viable cells continuously convert resazurin to resorufin, increasing the
overall color and fluorescence of the media surrounding cells.
Fluorescence intensity can be quantitatively determined with a
fluorescence microplate reader at excitation/emission 544 nm/590
nm (Spectramax Gemini).
For hormone-dependent cell proliferation assays in androgen-
deprived LNCaP cells, cells were seeded at 2 × 104 cells/mL in a 24-
well plate in triplicate. Cells were plated in phenol red free RPMI
GlutaMAX (Invitrogen) supplemented with 10% charcoal-stripped
FBS to deplete endogenous steroids 48 h prior to the assay, as
described in previous reports.43 The optimal condition for the
treatment was found to be 5 days and the concentration of DHT
included to stimulate the cells was 0.1 nM. Cells were treated with
different concentrations of test compounds with or without 0.1 nM
DHT to achieve a final concentration of 0.1% DMSO in each well. A
control for the vehicle was included to ensure that no effect on viability
could be detected. Media and treatments were replaced every second
day, after washing the cells twice with 1× PBS. Supernatants were
collected after 5 days for evaluation of secreted PSA levels, and cell
proliferation was assessed for the same plate using AlamarBlue in order
to exclude nonspecific effects due to toxicity issues.
Prostate Specific Antigen (PSA) ELISA. Secreted levels of
prostate specific antigen were evaluated with a commercially available
kit (Quantikine Human Kallikrein 3/PSA Immunoassay, R&D
systems). The assay was performed following manufacturer’s guide-
lines. In brief, 50 μL of standards and cell culture samples were added
to precoated wells containing assay diluent RD1W (R&D systems)
and incubated for 2 h at room temperature. Unbound material was
washed several times and 200 μL of horseradish peroxidase (HRP)
labeled PSA conjugate antibody was added to each well and further
incubated for 2 h at room temperature. Wells were washed and treated
with colored substrate (tetramethylbenzidine) for an additional 30
min, after which 50 μL of stop solution (2 N sulfuric acid) was added
per well and optical density (450 nm with correction at 540 nm) was
read with a plate reader within 30 min (Versamax).
Molecular Modeling. A virtual screen was designed to select
compounds mapping onto the peptide binding surface (AF2) of the
AR receptor, based on an ensemble of documented X-ray crystal
structures (PDB ID 1T73, 1T74, 1T76, 1T79, 1T7F, 1T7M, 1T7R,
and 1T7T).23 Molecular Operating Environment (MOE) software25
was employed to preprocess the proteins and to remove the
coactivator peptides from the complexes. An initial pharmacophore
was generated using the MOE pharmacophore elucidator and
considering the most significant features, which involved hydrophobic,
donor, and acceptor features. A second pharmacophore was developed
including two additional hydrophobic/aromatic features to represent
the Phe side chains present in the FxxLF coactivator motif (1T7R), so
as to increase the selectivity for AR over other families of nuclear
receptor. These pharmacophore models were then applied for in silico
screens of small-molecule commercial libraries to identify compounds
that resemble the “active principle” of the starting peptides.44
Database Preprocessing. A number of vendor databases were
selected for screening of ligands, including Amsterdam45 (5389
compounds), Peakdale46 (8188), Asinex47 Platinum collection (75
258), Specs48 (175 800), Maybridge49 (56 870), and ZINC50,51 (4.6
million) compounds. A Bayesian analysis was performed on the
peptide structures to estimate parameters of an underlying distribution
based on the observed distribution. The above databases were then
filtered for those compounds with properties similar to the peptides,
thus focusing the search on the AR ligand chemical space. Any salts or
duplicates were removed. All molecules were standardized for
stereochemistry and charges and ionized at a pH of 7.4 and all
calculable tautomers were enumerated. At this stage the conforma-
tional flexibility of the screening compounds was explored using the
Omega software52 (OpenEye Scientific package). A maximum of 50
conformations were generated for each molecule in the data set.
Compound Screening. The virtual molecules were overlaid on and
compared to the generated pharmacophore of the active ligands, and
those molecules that compared favorably were advanced for additional
virtual screening and scoring. The Fast Rigid Exhaustive Docking
(FRED)53 software as implemented in OpenEye Scientific’s package
was used to exhaustively examine all possible poses within the protein
site, filtering for shape complementarity and scoring. The smaller
databases (Amsterdam45 and Peakdale46) were screened on all 13
crystal structures and only ligands scoring well on more than one
crystal structure were considered. The larger databases Specs,48
Asinex,47 Maybridge,49 and ZINC50,51 were screened on the 1T7R
crystal structure.
Similarity Search. A structural similarity search was conducted on 1
and 2 using a Tanimoto coefficient of >70% on the Specs compound
database.48 Thirty-seven compounds were purchased and four small
molecules were selected for optimization and characterization studies
based on their improved on-target activity determined by TR-FRET.
Compound General Information. All screening compounds
described in this work were purchased as commercial samples from
Specs NV.48 Compound purity in all instances was greater than 95% as
determined by LCMS and NMR.
■ ASSOCIATED CONTENT
*S Supporting Information
Full experimental protocols for the identification of true AR
binders (TR-FRET and FP); TR-FRET data for GR, ER-α, and
ER-β (five point dose−response curves); FP data for PR at a
single point concentration; cell toxicity and hormone/CPA
dependent data on 22Rv1 cells; and a table of all compounds
tested during the investigation on AR TR-FRET. This material
is available free of charge via the Internet at http://pubs.acs.org.
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: lloyddg@tcd.ie. Phone: +353(1)8963527.
Present Address
∥The Marie Curie Laboratory for Membrane Proteins,
Department of Biology, National University of Ireland,
Maynooth, County Kildare, Ireland.
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
The authors thank the Irish Health Research Board (HRB)
(HRB/2007/2), Enterprise Ireland (EI- CFTD/06/110), and
Cancer Research Ireland (CRI) for research funding. The
Trinity Biomedical Sciences Institute is supported by a capital
infrastructure investment from Cycle 5 of the Irish Higher
Education Authority’s Programme for Research in Third Level
Institutions (PRTLI). L.C. thanks Prof. Robert Fletterick and
his group (Fletterick lab, UCSF) for helpful discussions. F.B.
thanks the support of the European Commission (Marie-Curie
grant, People FP7, Project Reference: 274988). 22Rv1 cells
were generously provided by Alice Vajda, Laure Marignol, and
Prof. Donal Hollywood in the Prostate Cancer Research group
(Institute of Molecular Medicine, Dublin).
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm201438f | J. Med. Chem. 2012, 55, 1635−16441642
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AF-1, activation function-1; AF-2, activation function-2; AR,
androgen receptor; BF-3, binding function-3; BPE, bovine
pituitary extract; CPA, cyproterone acetate; DBD, DNA-
binding domain; DHT, dihydrotestosterone; ELISA, enzyme-
linked immunosorbent assay; ER-α, estrogen receptor α; ER-β,
estrogen receptor β; FBS, fetal bovine serum; FP, fluorescence
polarization; FRED, fast rigid exhaustive docking; F12K,
Kaighn’s modification of Ham’s F-12 medium; GR, glucocorti-
coid receptor; HH, harmol hydrochloride; HRP, horseradish
peroxidase; K-SFM, keratinocyte serum free medium; LBD,
ligand binding domain; LBP, ligand binding pocket; LNCaP,
androgen-dependent human prostate cancer cell line; mP,
millipolarization units; MOE, molecular operating environ-
ment; NA, not active; NR, nuclear receptor; PC-3, androgen-
independent human prostate cancer cell line; PCa, prostate
cancer; PGC-1α, peroxisome proliferator-activated receptor γ
coactivator 1-α; PR, progesterone receptor; PP, pyrvinium
pamoate; PSA, prostate-specific antigen; PWR-1E, androgen-
dependent human prostatic cell line; RPMI, Roswell Park
Memorial Institute; SEM, standard error of the mean; SRC,
steroid receptor coactivator; Tb, terbium; tes, testosterone; TR-
FRET, time-resolved fluorescence resonance energy transfer;
VS, virtual screening; wt, wild-type; x, unspecified amino acid;
22Rv1, partially androgen-independent human prostate cancer
cell line
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